Stevens Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Stevens Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$960K	Buy	+7,513	New	+$938K	0.15%	92
2024 Q4	–	Sell	-17,022	Closed	-$1.68M	–	390
2024 Q3	$1.68M	Buy	+17,022	New	+$1.67M	0.24%	55
2024 Q2	–	Sell	-24,596	Closed	-$2.33M	–	349
2024 Q1	$2.33M	Buy	+24,596	New	+$2.28M	0.45%	44
2023 Q3	–	Sell	-12,644	Closed	-$1.05M	–	352
2023 Q2	$1.05M	Buy	12,644 +8,442	+201%	+$706K	0.22%	96
2023 Q1	$320K	Sell	4,202 -61,798	-94%	-$5.13M	0.08%	148
2022 Q4	$5.48M	Sell	66,000 -1,826	-3%	-$148K	3.46%	7
2022 Q3	$5.38M	Sell	67,826 -32,474	-32%	-$2.74M	3.45%	6
2022 Q2	$7.45M	Buy	100,300 +23,300	+30%	+$1.75M	5.18%	6
2022 Q1	$6.92M	Buy	77,000 +41,405	+116%	+$3.82M	1.51%	14
2021 Q4	$3.98M	Buy	35,595 +33,672	+1,751%	+$4.06M	0.92%	26
2021 Q3	$242K	Sell	1,923 -16,677	-90%	-$2.15M	0.1%	147
2021 Q2	$2.52M	Sell	18,600 -32,555	-64%	-$4.28M	0.74%	21
2021 Q1	$6.94M	Sell	51,155 -48,545	-49%	-$7.27M	3.82%	8
2020 Q4	$14M	Buy	99,700 +6,200	+7%	+$794K	6.89%	2
2020 Q3	$10.4M	Buy	+93,500	New	+$10.5M	3.87%	4

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Stevens Capital Management's XBI Position: Q1 2026 in Review

Stevens Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q1 2026: 7,513 shares worth $960K. The stake represents 0.15% of the portfolio and ranks #92 among its holdings. This is a return to the name: Stevens Capital Management previously reported a position in XBI as recently as Q3 2024.

Stevens Capital Management first reported a position in XBI in Q3 2020 and has held it in 15 quarters since. The position peaked at $14M in Q4 2020. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Stevens Capital Management held 7,513 shares of State Street SPDR S&P Biotech ETF worth $960K as of Q1 2026.
State Street SPDR S&P Biotech ETF was a new Stevens Capital Management position in Q1 2026.
State Street SPDR S&P Biotech ETF made up 0.15% of Stevens Capital Management's portfolio in Q1 2026, its #92 holding.
Stevens Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q3 2020 and has held it in 15 quarters since.
Stevens Capital Management's State Street SPDR S&P Biotech ETF position peaked at $14M in Q4 2020.
813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Stevens Capital Management's 13F filing for Q1 2026, filed 11 May 2026.